Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tianeptine is an atypical tricyclic antidepressant developed in the 1980s and used primarily for the treatment of major depressive disorder and anxiety in some European, Asian, and South American countries[1][2][5]. It is not approved for medical use in the United States but is sometimes sold as a dietary supplement or under various street names such as "gas station heroin"[2][3]. At low doses it has mood-stabilizing effects; at higher doses it acts like an opioid agonist and can cause euphoria and dependence[1][5]. Its mechanism of action was initially thought to involve serotonin reuptake enhancement but more recent research indicates that its main effects are due to modulation of glutamate receptor activity and full agonism at mu opioid receptors[1][5]. It also affects dopamine D2/3 receptors indirectly through downstream pathways. The drug has been associated with significant risks including addiction potential similar to opioids when misused or taken at high doses[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tianeptine.